Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7/ CCL20 in glioma

Xueran Chen; Zhen Wang; Huihui Ma; Shangrong Zhang; Haoran Yang; Hongzhi Wang; Zhiyou Fang

doi:10.18632/oncotarget.20525

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7/ CCL20 in glioma

Xueran Chen _, Zhen Wang, Huihui Ma, Shangrong Zhang, Haoran Yang, Hongzhi Wang and Zhiyou Fang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:93580-93592. https://doi.org/10.18632/oncotarget.20525

Metrics: PDF 3040 views | HTML 5340 views | ?

Abstract

Xueran Chen1,2, Zhen Wang1,2, Huihui Ma3,4, Shangrong Zhang1,2, Haoran Yang1,2, Hongzhi Wang1,2 and Zhiyou Fang1,2

1Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, 230031, China

2Anhui Province Key Laboratory of Medical Physics and Technology, Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, China

3Key Laboratory of Ion Beam Bioengineering, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, China

4Department of Radiation Oncology, First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, 230022, China

Correspondence to:

Xueran Chen, email: [email protected]

Zhiyou Fang, email: [email protected]

Keywords: melatonin, CCL20, epithelial–mesenchymal transition (EMT), glioma

Received: July 17, 2017 Accepted: August 01, 2017 Published: August 24, 2017

ABSTRACT

Tumor recurrence in gliomas is partly attributed to increased epithelial–mesenchymal transition (EMT) and enhanced tumor cell dissemination in the adjacent brain parenchyma. Thus, exploring effective strategies for against EMT-like changes in glioma invasion and recurrence will be important for glioma treatment. In this study, we investigated the roles of melatonin in hypoxia-induced EMT suppression, and found that melatonin could significantly suppress the release of the cytokine, CCL20, from cancer cells and antagonize glioma cell metastasis and invasion under hypoxic stress in glioma cells. Furthermore, our findings show that melatonin deregulates Smad7 expression to suppress TGFβ/Smad-mediated increase in CCL20 transcript levels and CCL20-induced EMT occurrence, suggesting a potential anti-EMT therapeutic role for melatonin in malignant transformation in gliomas.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20525

Publication Alerts

Research Papers:

Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7/ CCL20 in glioma

Abstract